腹膜偽黏液瘤(Pseudomyxoma peritonei, PMP)是一種罕見的、生長緩慢的邊緣惡性腫瘤。發病率大約為每年1-2人每百萬人口。該疾病主要源自胃腸道,但有時也可能起源於婦科器官。由於產生大量的黏液或明膠狀腹水,阻礙消化或器官功能,如果不治療,腫瘤和黏液將充滿腹腔導致嚴重症狀。目前PMP的治療基於減積手術和輔助性熱化學腹腔注射治療(HIPEC)。然而,HIPEC的副作用治療效果存在爭議。我們在此報告一名62歲的女性,她患有腹部鼓脹和體重消瘦超過6個月。在診斷為巨大盆腔腫瘤的情況下,進行了剖腹探查手術。病理報告顯示卵巢畸胎瘤引起的低級別假性黏液腹膜瘤。完成完整的減積手術後,我們將進行後續的腹膜內化療以及腹腔溫熱化療的輔助治療。基於此病例報告,我們對假黏液腹膜瘤的治療進行了回顧。
Pseudomyxoma peritonei (PMP) is a rare, slow-growing borderline malignancy tumor. The incidence rate was approximated at 1-2 people per million per year. The disease mostly originated from the gastrointestinal tract, but sometimes may arise from the Gynaecology system. As the abundant mucin or gelatinous ascites was produced, the tumors cause fibrosis of tissues and impede digestion or organ function, and if left untreated, the tumors and mucin will fill the abdominal cavity. The treatment for Pseudomyxoma peritonei (PMP) was currently based on cytoreduction surgery accompanied by adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). Nevertheless, the side effects of HIPEC made this treatment combination controversial.We hereby presented a 62-year-old woman who suffered from abdominal fullness and cachexia for over 6 months. Under the pre-operation diagnosis of a huge pelvic tumor, exploratory laparotomy surgery was performed. Pathological reported low-grade pseudomyxoma peritonei arising from mature cystic teratoma. After finishing the cytoreduction surgery, we planned to keep her under adjuvant therapy with intraperitoneal chemotherapy and HIPEC. Based on this case report, a review of the treatment of Pseudomyxoma peritonei was done.